Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Asep Medical Holdings Inc C.ASEP

Alternate Symbol(s):  SEPSF

ASEP Medical Holdings Inc. is a Canada-based company, which is in the business of acquiring research and development assets, technologies and/or businesses in the area of life sciences and medical diagnostics. The Company’s consolidates three development-stage companies, including Sepset Biosciences Inc., ABT Innovations Inc., and SafeCoat Medical Inc. It provides medical devices with an anti-microbial, antifouling coating through its SafeCoat Medical Inc. The Company provides diagnostic kits for predicting the onset of severe Sepsis and organ failure through its Sepset Biosciences Inc. The Company also offers peptide technology through its ABT Innovations Inc. and covers a range of therapeutic applications, including bacterial biofilm infections, anti-inflammatories, anti-infective immune-modulators and vaccine adjuvants. SafeCoat Medical Inc.'s technology incorporates self-assembling biocompatible polymers combined with conjugated antimicrobial peptides.


CSE:ASEP - Post by User

Post by Justdosomeddon Dec 24, 2021 5:53pm
113 Views
Post# 34261778

Huge Potential Market for ASEP

Huge Potential Market for ASEP
Asep Medical is a recently IPOd biotech company on the CSE. They’re focusing mainly on treating sepsis and the antibiotic-resistant market.
 
Sepsis is a deadly disease that affects 49M people per year and causes 11M deaths out of those 49M. So, they have a sizeable potential market since there are currently no approved drugs for biofilms on the market, with 65% of the sepsis infections coming from biofilms.
 
$ASEP has two main approaches for treating Sepsis and related diseases.
 
- Diagnostics: They developed a new diagnostics assay to confirm sepsis using the immune response instead of looking for a specific pathogen. This makes the testing far more sensitive and efficient, taking only 1 hour to get results and begin treatment instead of the usual 24 hours.
 
- Therapeutics: $ASEP also developed a peptide technology that addresses the ineffectiveness of current treatments by suppressing biofilm regrowth and reducing inflammation Plus, it has potent activity against all clinically relevant antibiotic-resistant biofilms.
 
With the two main technologies, things are looking promising for the company already. Commercialization is expected to hit in the middle of next year, and we should see significant interest in their technologies. $ASEP isn't just bringing a new drug to the market, they're saving lives. Additionally, they have an experienced management team and around $15M awarded through non-dilutive research grants.
 
Overall, it's definitely worth it to keep an eye on these guys. Their work will help bring the medical industry to the next level through the novel approaches and technology they're bringing to the market. The stock has been holding out at around $0.50 with support levels in the mid $0.40 range. With the downward momentum finally slowing, it's looking like a pretty attractive entry point with a $28M market cap.
<< Previous
Bullboard Posts
Next >>